CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer

Journal of the National Cancer Institute

Volumn 102, Issue 19, 2010, Pages 1496-1512

  Wang, Xinhui ^a,b   Osada, Takuya ^c   Wang, Yangyang ^a   Yu, Ling ^a,b   Sakakura, Koichi ^a,b   Katayama, Akihiro ^a,b   McCarthy, James B ^d   Brufsky, Adam ^b   Chivukula, Mamatha ^b   Khoury, Thaer ^e   Hsu, David S ^c   Barry, William T ^c   Lyerly, H Kim ^c   Clay, Timothy M ^c   Ferrone, Soldano ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD24 ANTIGEN; CHONDROITIN SULFATE PROTEOGLYCAN 4; HERMES ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 225.28; PROTEOCHONDROITIN SULFATE; UNCLASSIFIED DRUG; CSPG4 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CANCER RECURRENCE; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MITOSIS; MOUSE; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; AGED; ANIMAL; BREAST NEOPLASMS; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; EPIDEMIOLOGY; FLOW CYTOMETRY; IMMUNOBLOTTING; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MELANOMA; METABOLISM; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; XENOGRAFT;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHONDROITIN SULFATE PROTEOGLYCANS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOTHERAPY; LUNG NEOPLASMS; MELANOMA; MEMBRANE PROTEINS; MICE; PLEURAL EFFUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957829001     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq343     Document Type: Article

References (76)

1. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
2. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418-8423.
3. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classifcation and prognosis based on gene expression profles from a population-based study. Proc Natl Acad Sci U S A. 2003;100:10393-10398.
4. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
5. Rakha EA, El-Sayed ME, Green AR, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007;25:4772-4778.
6. Rakha EA, Tan DS, Foulkes WD, et al. Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res. 2007;9:404. author reply 5.
7. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol. 2009;20:1913-1927.
8. Eyler CE, Rich JN. Survival of the fttest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008;26:2839-2845.
9. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res. 2010;16:3113-3120.
10. Honeth G, Bendahl PO, Ringner M, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53.
11. Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther. 2009;4:50-60.
12. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res. 2010;16:876-887.
13. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Med Oncol. 2010. doi:10.1007/s12032-010-9530-3.
14. Petrelli F, Cabiddu M, Ghilardi M, Barni S. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based? Expert Opin Investig Drugs. 2009;18:1467-1477.
15. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol. 2004;24:267-296.
16. Wilson BS, Imai K, Natali PG, Ferrone S. Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer. 1981; 28:293-300.
17. Wang X, Wang Y, Yu L, et al. CSPG4 in cancer: multiple roles. Curr Mol Med. 2010;10:419-429.
18. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A. 1992;89:466-470.
19. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515-527.
20. Sabe I, Andritsch I, Mangoud A, Awad AS, Khalifa A, Krishan A. Flow cytometric analysis of estrogen receptor expression in isolated nuclei and cells from mammary cancer tissues. Cytometry. 1999;36:131-139.
21. Gritzapis AD, Baxevanis CN, Missitzis I, et al. Quantitative fuorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assay. Breast Cancer Res Treat. 2003;80:1-13.
22. Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S. Differential immu-nogenicity of two peptides isolated by high molecular weight-melanoma- associated antigen-specifc monoclonal antibodies with different affnities. J Immunol. 2005;174:7104-7110.
23. Perosa F, Ferrone S. Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR, DP monoclonal antibody CR11-462. Hum Immunol. 1988;23:255-269.
24. Kusama M, Kageshita T, Chen ZJ, Ferrone S. Characterization of synge-neic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J Immunol. 1989;143:3844-3852.
25. Chen ZJ, Yang H, Kageshita T, Ferrone S. Human high-molecular-weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371. Cancer Res. 1991;51:4790-4797.
26. Temponi M, Gold AM, Ferrone S. Binding parameters and idiotypic profle of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen. Cancer Res. 1992;52:2497-2503.
27. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specifc monoclonal antibodies for fow cytometry and immunohistochemical staining. Tissue Antigens. 2003; 62:385-393.
28. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol. 1986;137:2299-2306.
29. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S. Purifcation of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purifcation. Hybridoma. 1989;8:85-95.
30. Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat. 2008;108:191-201.
31. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defned by fve biomarkers has superior prognostic value than triple-negative pheno-type. Clin Cancer Res. 2008;14:1368-1376.
32. Kageshita T, Kuriya N, Ono T, et al. Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. Cancer Res. 1993;53:2830-2833.
33. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identifcation of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-3988. (Pubitemid 36418143)
34. Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene. 2006;25:2873-2884.
35. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A. 1980;77:2936-2940.
36. Wu WJ, Tu S, Cerione RA. Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell. 2003;114:715-725.
37. Ko E, Luo W, Peng L, Wang X, Ferrone S. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res. 2007;67:7875-7884.
38. Armitage P, Berry G. Statistical Methods in Medical Research. 3rd ed. London: Blackwell; 1994.
39. Burg MA, Nishiyama A, Stallcup WB. A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. Exp Cell Res. 1997;235:254-264.
40. Burg MA, Grako KA, Stallcup WB. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol. 1998;177:299-312.
41. Yang J, Price MA, Neudauer CL, et al. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol. 2004;165:881-891.
42. Makagiansar IT, Williams S, Mustelin T, Stallcup WB. Differential phos-phorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration. J Cell Biol. 2007;178:155-165.
43. Makagiansar IT, Williams S, Dahlin-Huppe K, Fukushi J, Mustelin T, Stallcup WB. Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility. J Biol Chem. 2004;279:55262-55270.
44. Chekenya M, Krakstad C, Svendsen A, et al. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 2008;27:5182-5194.
45. Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY, Tokuda Y. Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci. 2007;98:1889-1892.
46. Abeyweera TP, Chen X, Rotenberg SA. Phosphorylation of alpha6-tubulin by protein kinase Calpha activates motility of human breast cells. J Biol Chem. 2009;284:17648-17656.
47. Hendzel MJ, Wei Y, Mancini MA, et al. Mitosis-specifc phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;106:348-360.
48. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carci-nogenesis. Lab Invest. 2002;82:1525-1533.
49. Mani SA, Yang J, Brooks M, et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A. 2007;104:10069-10074.
50. Rettig WJ, Real FX, Spengler BA, Biedler JL, Old LJ. Human melanoma proteoglycan: expression in hybrids controlled by intrinsic and extrinsic signals. Science. 1986;231:1281-1284.
51. Matthay RA, Coppage L, Shaw C, Filderman AE. Malignancies metastatic to the pleura. Invest Radiol. 1990;25:601-619.
52. Fenton KN, Richardson JD. Diagnosis and management of malignant pleural effusions. Am J Surg. 1995;170:69-74.
53. Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12:5615-5621.
54. Eisenmann KM, McCarthy JB, Simpson MA, et al. Melanoma chon-droitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol. 1999;1:507-513.
55. Fang X, Burg MA, Barritt D, Dahlin-Huppe K, Nishiyama A, Stallcup WB. Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. Mol Biol Cell. 1999; 10:3373-3387.
56. Stallcup WB, Dahlin-Huppe K. Chondroitin sulfate and cytoplasmic domain-dependent membrane targeting of the NG2 proteoglycan promotes retraction fber formation and cell polarization. J Cell Sci. 2001;114:2315-2325.
57. Schlingemann RO, Rietveld FJ, de Waal RM, Ferrone S, Ruiter DJ. Expression of the high molecular weight melanoma-associated antigen bypericytes during angiogenesis in tumors and in healing wounds. Am J Pathol. 1990;136:1393-1405.
58. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3:301-313.
59. Yang J, Price MA, Li GY, et al. Melanoma proteoglycan modifes gene expression to stimulate tumor cell motility, growth, and epithelial-to- mesenchymal transition. Cancer Res. 2009;69:7538-7547
60. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel). 1995;154:8-20.
61. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-454.
62. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453-458.
63. Rae JM, Ramus SJ, Waltham M, et al. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis. 2004;21:543-552.
64. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000;24:227-235.
65. Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC. Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol. 2002;55:294-299.
66. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat. 2007;104:13-19.
67. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 2009;69:5292-5293.
68. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastu-zumab (Herceptin). Semin Oncol. 1999;26:60-70.
69. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientifc update. Semin Oncol. 2001;28:4-11.
70. Herberman RB, Reynolds CW, Ortaldo JR. Mechanism of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol. 1986;4:651-680.
71. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
72. Palma V, Lim DA, Dahmane N, et al. Sonic hedgehog controls stem cell behavior in the postnatal and adult brain. Development. 2005;132:335-344.
73. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843-850. (Pubitemid 40558990)
74. Kadoya K, Fukushi J, Matsumoto Y, Yamaguchi Y, Stallcup WB. NG2 proteoglycan expression in mouse skin: altered postnatal skin development in the NG2 null mouse. J Histochem Cytochem. 2008;56:295-303.
75. Huang FJ, You WK, Bonaldo P, Seyfried TN, Pasquale EB, Stallcup WB. Pericyte defciencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse. Dev Biol. 2010;344:1035-1046.
76. Erfurt C, Sun Z, Haendle I, et al. Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity. J Immunol. 2007;178:7703-7709.